Detalhe da pesquisa
1.
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation
; 148(8): 651-660, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603600
2.
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Am Heart J
; 271: 38-47, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401646
3.
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
Cardiovasc Diabetol
; 22(1): 100, 2023 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120538
4.
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
Cardiovasc Diabetol
; 22(1): 176, 2023 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37438734
5.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med
; 380(24): 2295-2306, 2019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30990260
6.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Am J Kidney Dis
; 79(2): 244-256.e1, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34029680
7.
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Diabetologia
; 64(10): 2147-2158, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415356
8.
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Am Heart J
; 233: 141-148, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358942
9.
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab
; 23(1): 252-257, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954617
10.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Circulation
; 140(9): 739-750, 2019 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291786
11.
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 19(6): 897-900, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28083972
12.
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.
Ann Intern Med
; 174(3): 431-432, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721528
13.
Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points.
Clin J Am Soc Nephrol
; 19(4): 429-437, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38099944
14.
A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease.
Kidney360
; 3(9): 1599-1602, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36245651
15.
Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
Thromb Haemost
; 101(3): 422-7, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19277401
16.
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Diabetes Ther
; 7(1): 125-37, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26758563
17.
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Postgrad Med
; 128(4): 346-55, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26878357
18.
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Drugs Aging
; 33(7): 511-22, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27357173
19.
Pharmacological prevention of venous thromboembolism in medical patients at risk.
Am J Cardiovasc Drugs
; 5(6): 409-15, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16259529
20.
New antithrombotics in the prevention of thromboembolic disease.
Eur J Intern Med
; 16(4): 257-66, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16084352